Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have earned a consensus rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $17.80.
Several equities research analysts recently weighed in on the company. HC Wainwright raised Artiva Biotherapeutics to a “buy” rating and set a $12.00 price objective on the stock in a report on Wednesday, June 11th. Cantor Fitzgerald cut their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, March 25th. Needham & Company LLC cut their price objective on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Finally, Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th.
View Our Latest Stock Analysis on ARTV
Artiva Biotherapeutics Stock Down 0.6%
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15). As a group, analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of ARTV. Deutsche Bank AG bought a new position in shares of Artiva Biotherapeutics during the fourth quarter worth about $216,000. Norges Bank bought a new stake in Artiva Biotherapeutics in the fourth quarter valued at approximately $302,000. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after purchasing an additional 7,151 shares during the period. JPMorgan Chase & Co. raised its holdings in Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after purchasing an additional 26,893 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Artiva Biotherapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter.
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Featured Articles
- Five stocks we like better than Artiva Biotherapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- There Are Different Types of Stock To Invest In
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Options Trading – Understanding Strike Price
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.